Do patients with fibromyalgia syndrome and healthy people differ in their opinions on placebo effects in routine medical care?
Johan (Hans) P.A. van Lennep (Universiteit Leiden, The Center for Interdisciplinary PlaceboStudies Leiden)
Simone Meijer (Universiteit Leiden, The Center for Interdisciplinary PlaceboStudies Leiden)
Merve Karacaoglu (Universiteit Leiden, The Center for Interdisciplinary PlaceboStudies Leiden)
Ralph Rippe (Universiteit Leiden)
Kaya J. Peerdeman (The Center for Interdisciplinary PlaceboStudies Leiden, Universiteit Leiden)
H. van Middendorp (The Center for Interdisciplinary PlaceboStudies Leiden, Universiteit Leiden)
A.W.M. Evers (Universiteit Leiden, TU Delft - Society, Culture and Critique, The Center for Interdisciplinary PlaceboStudies Leiden, Leiden University Medical Center)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
Objectives: Placebo effects can relieve acute and chronic pain in both research and clinical treatments by learning mechanisms. However, the application of placebo-based treatment strategies in routine medical care is questioned. The current study investigated the opinions of patients with fibromyalgia and healthy controls regarding learning of placebo effects and their practical applications. Method: An online survey asked 158 age- and sex-matched adult patients and controls (79 per group) to rate the perceived influence of various placebo learning mechanisms on pain relief, and the acceptability and perceived effectiveness of placebo-based strategies (open-label, closed-label, dose-extending, and treatment-enhancing strategies). Respondents' knowledge about placebo effects was obtained through a 7-item quiz. Results: The groups did not differ in the perceived influence of placebo learning mechanisms on pain relief (p = 0.217). Controls considered closed-label and treatment-enhancing strategies more acceptable than patients (p = 0.003 and p < 0.001), whereas controls perceived all strategies more effective. In both groups, closed-label strategies were significantly less acceptable than any other strategy (p-values < 0.001), and treatment-enhancing or dose-extending strategies were most acceptable. Higher acceptability was predicted by higher perceived effectiveness ratings (p < 0.001). Also, increased placebo knowledge was related to higher acceptability (p = 0.03) and perceived effectiveness (p < 0.001). Discussion: This survey suggests that both the medical history of patients and knowledge about placebo effects affect the acceptability and perceived effectiveness of placebo-based strategies. Furthermore, strategies that are transparent, assumed effective, or combined with existing medical treatments are deemed most acceptable. Keeping these factors in mind is essential for the clinical implementation of placebo-based strategies in routine medical care.